7SS Stock Chart & Stats
€0.19
<€0.01(7.63%)
At close: 4:00 PM EST
€0.19
<€0.01(7.63%)
Day’s Range― - ―
52-Week Range€0.09 - €0.22
Previous CloseN/A
Volume0.00
Average Volume (3M)43.00
Market Cap
€80.60M
Enterprise Value-€1.40B
Total Cash (Recent Filing)€1.77B
Total Debt (Recent Filing)€6.18M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding735,837,770
10 Day Avg. Volume87
30 Day Avg. Volume43
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Partnered Commercialization ModelBrii’s reliance on licensing and pharmaceutical partnerships can broaden access to drug candidates while sharing development costs and creating milestone or royalty opportunities. This asset-light model may support commercialization without requiring the company to fund every stage independently.
Low Financial LeverageVery low leverage reduces financial pressure and preserves flexibility while Brii funds its development and commercialization activities. A modest debt burden also limits interest-related strain and gives the company more room to manage operating volatility than a highly indebted biotechnology business.
Reduced Annual Loss And Cash BurnThe reduction in the 2025 loss and cash outflow indicates some progress in controlling the rate of financial deterioration. Although the company remains unprofitable and cash-consuming, continued improvement could extend liquidity and create a better foundation for future commercialization efforts.
Bears Say
Persistent UnprofitabilityOngoing losses and deeply negative margins show that Brii has not yet established sustainable earnings from its development and commercialization activities. Continued unprofitability can constrain reinvestment, increase reliance on funding, and make future operating progress dependent on successful product execution.
Sharp Revenue ContractionA material revenue decline after prior volatility weakens evidence of durable commercial traction and operating scale. If this pattern persists, lower revenue absorption could make fixed business costs harder to cover and reduce the resources available for advancing the company’s pipeline and marketed products.
Persistent Negative Cash FlowConsistently negative operating and free cash flow means Brii is not currently funding its activities from internally generated cash. The resulting need for existing liquidity or external funding can limit strategic flexibility and leave the business exposed if commercialization does not improve cash generation.
Brii Biosciences Limited News
7SS FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was €0.09 and its highest was €0.22 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is €80.60M.
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Mar 19, 2027 which is in 138 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Aug 20, 2026. The company reported -€0.018 earnings per share for the quarter, missing the consensus estimate of -€0.014 by -€0.004.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 735,837,770 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -€0.018 in its last earnings report, missing expectations of -€0.014. Following the earnings report the stock price went up 5.155%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in DE:7SS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brii Biosciences Limited
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Technical Analysis
Mabpharm Limited
―
Clover Biopharmaceuticals Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Transcenta Holding Limited
―
AIM Vaccine Co., Ltd. Class H
―